Yahoo Finance

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

ESTERO, FLORIDA / ACCESS Newswire / January 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending ...
Yahoo Finance

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset ...
The Indianapolis Star

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disorders Alprazolam, sold under the brand name Xanax® among others, ...
Milwaukee Journal Sentinel

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

ESTERO, FLORIDA / ACCESS Newswire / January 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending ...